Dynavax initiates clinical trial in non-small cell lung cancer with inhaled TLR9 agonist
Dynavax announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 agonist, DV281, in patients with non-small cell lung cancer. This multi-center, open label trial is designed to evaluate safety and identify the optimal dose. October 19, 2017